Profile data is unavailable for this security.
About the company
Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.
- Revenue in GBP (TTM)15.18k
- Net income in GBP-8.96m
- Incorporated2020
- Employees14.00
- LocationVerici DX PLC393 Nichol Mill Lane, Suite 200FRANKLIN 37067United StatesUSA
- Websitehttps://vericidx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shield Therapeutics PLC | 7.21m | -46.89m | 9.58m | 28.00 | -- | 0.3223 | -- | 1.33 | -0.1549 | -0.1549 | 0.0151 | 0.038 | 0.1691 | 1.80 | 0.9805 | -- | -109.95 | -42.77 | -129.39 | -48.12 | 44.76 | 79.44 | -650.12 | -274.35 | 2.64 | -124.94 | 0.1756 | -- | 261.55 | 53.86 | -151.04 | -- | -7.68 | -- |
| Proteome Sciences plc | 5.03m | -2.44m | 10.36m | 35.00 | -- | -- | -- | 2.06 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Kanabo Group PLC | 813.00k | -4.66m | 10.75m | 20.00 | -- | 0.7069 | -- | 13.22 | -0.0108 | -0.0108 | 0.0019 | 0.024 | 0.047 | 8.56 | 27.10 | 40,650.00 | -26.95 | -75.82 | -28.68 | -82.57 | 23.12 | -- | -572.94 | -1,786.10 | 7.96 | -13.03 | 0.041 | -- | 726.03 | -- | -50.96 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 10.89m | 2.00 | -- | -- | -- | 74.24 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 12.17m | 82.00 | -- | 6.71 | -- | 2.28 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.48m | 12.87m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
| Synairgen plc | 0.00 | -9.99m | 13.27m | 30.00 | -- | 0.8313 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
| Provexis plc | 598.08k | -496.59k | 13.58m | 2.00 | -- | 13.54 | -- | 22.70 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Genincode PLC | 1.72m | -6.73m | 13.71m | 28.00 | -- | 1.56 | -- | 7.99 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Destiny Pharma PLC | 0.00 | -5.97m | 15.96m | 20.00 | -- | 1.34 | -- | -- | -0.0759 | -0.0759 | 0.00 | 0.1251 | 0.00 | -- | -- | 0.00 | -48.68 | -47.98 | -52.87 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.38m | 3.00 | -- | 1.73 | -- | 25.23 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 17.42m | 56.00 | -- | 26.52 | -- | 15.12 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
| Verici DX PLC | 15.18k | -8.96m | 17.51m | 14.00 | -- | 2.30 | -- | 1,153.26 | -0.0526 | -0.0526 | 0.00009 | 0.0314 | 0.0013 | -- | 0.1152 | 1,012.28 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| LungLife AI Inc | 36.76k | -4.33m | 18.32m | 19.00 | -- | 1.20 | -- | 498.31 | -0.1697 | -0.1697 | 0.0014 | 0.2481 | 0.0038 | -- | 0.1474 | 1,934.83 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 18.54m | 11.00 | -- | 4.82 | -- | 114.66 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 21.27m | 17.00 | -- | 6.61 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
Data as of Apr 26 2024. Currency figures normalised to Verici DX PLC's reporting currency: UK Pound GBX
36.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Harwood Capital LLPas of 20 Feb 2024 | 37.65m | 15.52% |
| Octopus Investments Ltd.as of 20 Feb 2024 | 21.65m | 8.92% |
| Unicorn Asset Management Ltd.as of 31 Mar 2024 | 20.35m | 8.39% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2023 | 6.55m | 2.70% |
| Dowgate Wealth Ltd.as of 28 Mar 2024 | 1.09m | 0.45% |
| Schroder Investment Management Ltd.as of 31 Dec 2023 | 271.93k | 0.11% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Dec 2022 | 137.27k | 0.06% |
| Discover Capital GmbHas of 30 Jun 2023 | 40.00k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 2.79k | 0.00% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 966.00 | 0.00% |
More ▼
Data from 31 Jan 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
